Fifteen collaborative public-private research projects aiming to address bottlenecks in the pharmaceutical R&D process are to receive Euro 246 million from the European Commission (EC) and European Federation of Pharmaceutical Industries and Associations (EFPIA) companies, as part of the Innovative Medicines Initiative (IMI) imi.europa.eu, a public-private partnership between the EC and the European pharmaceutical industry.
The EFPIA maintains the initiative, representing the first time that competing pharmaceutical companies will pool their resources, together with those of research organizations, patient groups, and other stakeholders, to develop generic knowledge.
The overall aim of the IMI is to encourage the discovery and development of better drugs, and improve the competitiveness of the European pharma industry. The first 15 projects, selected from some 150 applications, will now go through the final negotiation stage. A second call for proposals in the fields of oncology, infectious disease diagnosis, chronic inflammatory diseases, and knowledge management, is scheduled for later this year.